Does 1,25(OH)2D3 accelerate spinal bone loss? A controlled therapeutic trial in 70-year-old women.
The progress of spinal bone loss was monitored by measurements of the vertebral body height of T6 to L5 in seventy 70-year-old women who participated in a controlled, double-blind therapeutic trial. They were treated for one year by 1,25(OH)2D3, 0.50 micrograms a day (or less if hypercalcemia occurred) and cyclical estrogen/gestagen, alone or combined, or placebo. Sufficient calcium intake was ensured in all. The vertebral body height decreased significantly, by 1%, in both of the 1,25(OH)2D3 groups, whereas it remained unchanged in the hormone and the placebo + calcium group. This observation does not encourage the use of 1,25(OH)2D3 for prevention or treatment of postmenopausal bone loss.
D000368:Aged; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002136:Calcium, Dietary / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage / Q000627:therapeutic use; D004964:Estriol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology; D006801:Humans; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D010024:Osteoporosis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011859:Radiography; D011897:Random Allocation; D013124:Spinal Injuries / Q000209:etiology; D013131:Spine / Q000000981:diagnostic imaging*
D002136:Calcium, Dietary; D004338:Drug Combinations; D004958:Estradiol; C032040:Trisequens; D004964:Estriol; D002117:Calcitriol; D009640:Norethindrone